Shots:

• Merck allied with ISB and a consortium of companies to investigate the molecular mechanisms of SARS-CoV-2 Infection and to identify new targets for potential COVID-19 therapeutics and vaccines
• The collaboration supports the trial led by ISB and Swedish Medical Center in Seattle. By collecting blood and nasal swabs at different times following a patient’s diagnosis- the researchers plan to accumulate a large data set that incorporates patients’ genomes- proteomes and metabolomes + single-cell analytics of the evolving immune system response and the infection’s effect on different organs
• Merck will provide research funding and work with ISB researchers to identify targets for drugs- Ab & vaccines and will initially analyze samples from 200 patients with the potential to expand to 300. Additionally- Merck signed an agreement with BARDA to receive funding for supporting the company’s effort

Click here ­to­ read full press release/ article 

Ref: Merck | Image: Merck